RNA-binding Protein Musashi1 Modulates Glioma Cell Growth Through the Post-transcriptional Regulation of Notch and PI3 Kinase/Akt Signaling Pathways
Overview
Authors
Affiliations
Musashi1 (MSI1) is an RNA-binding protein that plays critical roles in nervous-system development and stem-cell self-renewal. Here, we examined its role in the progression of glioma. Short hairpin RNA (shRNA)-based MSI1-knock down (KD) in glioblastoma and medulloblastoma cells resulted in a significantly lower number of self renewing colony on day 30 (a 65% reduction), compared with non-silencing shRNA-treated control cells, indicative of an inhibitory effect of MSI1-KD on tumor cell growth and survival. Immunocytochemical staining of the MSI1-KD glioblastoma cells indicated that they ectopically expressed metaphase markers. In addition, a 2.2-fold increase in the number of MSI1-KD cells in the G2/M phase was observed. Thus, MSI1-KD caused the prolongation of mitosis and reduced the cell survival, although the expression of activated Caspase-3 was unaltered. We further showed that MSI1-KD glioblastoma cells xenografted into the brains of NOD/SCID mice formed tumors that were 96.6% smaller, as measured by a bioluminescence imaging system (BLI), than non-KD cells, and the host survival was longer (49.3±6.1 days vs. 33.6±3.6 days; P<0.01). These findings and other cell biological analyses suggested that the reduction of MSI1 in glioma cells prolonged the cell cycle by inducing the accumulation of Cyclin B1. Furthermore, MSI1-KD reduced the activities of the Notch and PI(3) kinase-Akt signaling pathways, through the up-regulation of Numb and PTEN, respectively. Exposure of glioma cells to chemical inhibitors of these pathways reduced the number of spheres and living cells, as did MSI1-KD. These results suggest that MSI1 increases the growth and/or survival of certain types of glioma cells by promoting the activation of both Notch and PI(3) kinase/Akt signaling.
The oncogene Musashi1 encodes novel miRNAs in breast cancer.
Lachinani L, Forouzanfar M, Dormiani K, Mohammad Soltani B, Dolatshahi K, Hakimian S Sci Rep. 2023; 13(1):13710.
PMID: 37607966 PMC: 10444885. DOI: 10.1038/s41598-023-40666-9.
He Z, Ni Q, Li X, Zhao M, Mo Q, Duo Y Heliyon. 2023; 9(6):e17387.
PMID: 37408905 PMC: 10318449. DOI: 10.1016/j.heliyon.2023.e17387.
Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance.
Nairuz T, Mahmud Z, Manik R, Kabir Y Stem Cell Rev Rep. 2023; 19(6):1577-1595.
PMID: 37129728 DOI: 10.1007/s12015-023-10529-x.
Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
Kitagawa A, Osawa T, Noda M, Kobayashi Y, Aki S, Nakano Y Br J Cancer. 2023; 128(12):2206-2217.
PMID: 37076565 PMC: 10241955. DOI: 10.1038/s41416-023-02256-4.
Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.
Langdon C Biomolecules. 2023; 13(2).
PMID: 36830628 PMC: 9953540. DOI: 10.3390/biom13020259.